Skip to content

Screening and early detection

TL;DR — Colorectal screening works through two mechanisms: detect cancer earlier and prevent cancer by finding/removing precursors. No test has a population effect independent of participation, diagnostic colonoscopy and treatment. USPSTF recommends average-risk screening from 45–75 and individualized screening from 76–85, using multiple acceptable strategies (US Preventive Services Task Force 2021, PMID 34003218). Randomized flexible-sigmoidoscopy trials show durable incidence and mortality reductions; NordICC colonoscopy invitation produced a 10-year incidence risk ratio of 0.82 and mortality risk ratio of 0.90 with 42% uptake, leaving the mortality CI compatible with no effect (Bretthauer 2022, PMID 36214590; Wooldrage 2024, PMID 39038482). FIT is scalable and associated with lower mortality when repeated, but positive-test colonoscopy delays break the chain (Doubeni 2024, PMID 39028667). Stool-DNA and blood tests may improve one-time completion, yet lower advanced-precursor sensitivity can trade cancer detection for less prevention (Imperiale 2024, PMID 38477986; Chung 2024, PMID 38477985).

Screening is a pathway, not a test

Pathway step Quality measure Failure consequence
Identify eligible population Denominator completeness Unequal invitation
Offer acceptable options Informed choice and access Refusal or mismatch with preference
Complete initial test Participation rate No biological opportunity for benefit
Resolve positive noninvasive test Timely colonoscopy Delayed cancer diagnosis and precursor removal
Perform high-quality colonoscopy Prep, cecal intubation, detection, resection Missed or incompletely removed lesion
Assign correct interval Structured result and recall Overuse or delayed surveillance
Treat detected disease Time to multidisciplinary care Stage progression and harm
Repeat when required Longitudinal adherence FIT benefit decays after missed rounds

Programs should report each transition. A high mailing rate can coexist with low diagnostic completion; a high colonoscopy completion rate can coexist with poor adenoma detection.

Average-risk eligibility and age

USPSTF gives a grade A recommendation for ages 50–75 and grade B for ages 45–49; ages 76–85 are selective based on health, prior screening and preference (US Preventive Services Task Force 2021, PMID 34003218). The American Cancer Society likewise moved average-risk initiation to 45 (Wolf 2018, PMID 29846947).

Age 45 is a policy threshold, not the onset of disease. Earlier screening is required for defined hereditary syndromes, inflammatory bowel disease, prior advanced lesions and some family histories. Conversely, limited life expectancy and prior negative screening can make harms outweigh delayed benefit in older adults.

Strategy comparison

Strategy Typical interval framework Cancer detection Precursor prevention Principal harm/burden
Annual FIT Every year Good single-round CRC sensitivity Indirect; only through follow-up colonoscopy Repetition and false positives
Stool DNA-FIT Every 1–3 years by jurisdiction Higher CRC sensitivity than FIT in cross-sectional studies Advanced-precursor sensitivity remains moderate More positives/colonoscopies and cost
Flexible sigmoidoscopy Once or every 5–10 years Distal visualization Direct distal polypectomy Proximal colon not directly examined
Colonoscopy About every 10 years after high-quality negative exam Whole-colon visualization Direct polypectomy Perforation, bleeding, sedation, preparation, capacity
CT colonography About every 5 years Structural whole-colon exam Requires colonoscopy for removal Radiation and extracolonic findings
Blood cfDNA Interval still evolving Convenient cancer signal Low advanced-precursor sensitivity False reassurance and downstream workup

Intervals depend on guideline, test generation and prior findings. A positive FIT, stool-DNA, CT-colonography or blood test is not “screening complete” until diagnostic evaluation is resolved.

FIT

FIT detects human globin and can use quantitative thresholds. A meta-analysis reported pooled sensitivity around 0.79 and specificity around 0.94 for colorectal cancer at commonly used thresholds, with substantial threshold and sampling heterogeneity (Lee 2014, PMID 24658694).

Design choice Higher sensitivity effect Higher specificity effect
Lower hemoglobin threshold More cancers/advanced lesions detected More colonoscopies
Two samples May recover intermittently bleeding lesions Greater participant burden
Annual repetition Cumulative detection improves Requires durable adherence
Centralized mailing/navigation Raises reach Requires tracking infrastructure

Organized screening among Kaiser Permanente members associated FIT participation with lower colorectal-cancer death; because participation was not randomized, residual healthy-user and care-engagement confounding remains (Doubeni 2024, PMID 39028667).

COLONPREV randomized invitation to colonoscopy or biennial FIT and reported mortality outcomes after long follow-up, directly comparing strategy invitations rather than test accuracy (Castells 2025, PMID 40158525). Strategy trials are especially valuable because they incorporate uptake and repeated adherence.

Colonoscopy

Colonoscopy examines the whole colon, biopsies cancer and removes precursors in one procedure. Its protective effect varies by endoscopist and by lesion type.

NordICC randomized 84,585 adults to invitation or usual care. At 10 years, colorectal-cancer incidence was 0.98% versus 1.20% (risk ratio 0.82, 95% CI 0.70–0.93), and colorectal-cancer death 0.28% versus 0.31% (risk ratio 0.90, 95% CI 0.64–1.16); 42% underwent colonoscopy (Bretthauer 2022, PMID 36214590).

Longer NordICC follow-up subsequently reported durable incidence effects and evolving mortality estimates; interpretation remains invitation-based because per-protocol comparisons sacrifice randomization (Kaminski 2026, PMID 42102826).

Colonoscopy quality

Metric Why it matters
Adequate bowel preparation Enables mucosal inspection
Cecal intubation Confirms complete examination
Adenoma detection rate Strong endoscopist-level outcome correlate
Proximal serrated detection Captures flat serrated pathway lesions
Withdrawal inspection Process supporting detection
Complete resection Prevents residual lesion growth
Complication rate Balances benefit and harm

Among 314,872 colonoscopies by 136 gastroenterologists, each 1-percentage-point increase in adenoma detection rate associated with a 3% decrease in interval-cancer risk (adjusted HR 0.97) (Corley 2014, PMID 24693890). Other cohorts linked higher adenoma detection with lower colorectal-cancer incidence and mortality (Wieszczy 2017, PMID 28842054; Waldmann 2021, PMID 33878471).

These associations support quality improvement but do not justify indiscriminate removal of diminutive non-neoplastic tissue. Detection, accurate characterization and complete safe resection must rise together.

Flexible sigmoidoscopy

Randomized trials provide the strongest endoscopic mortality evidence. UK Flexible Sigmoidoscopy Screening 21-year follow-up found sustained reductions in colorectal-cancer incidence and mortality after once-only screening (Wooldrage 2024, PMID 39038482). The Italian SCORE trial and US PLCO also showed long-term incidence/mortality effects, with differences by sex, site and contamination (Senore 2022, PMID 34748376; Miller 2019, PMID 30502933).

The Norwegian trial reported different effectiveness in women and men, illustrating that distal examination protects less consistently against proximal-predominant disease (Holme 2018, PMID 29710125).

Sigmoidoscopy evidence cannot be copied directly to colonoscopy: reach, preparation, complication profile and uptake differ. It nonetheless proves that endoscopic detection/removal can reduce mortality in randomized population settings.

Multitarget stool DNA

The DeeP-C cross-sectional study compared multitarget stool DNA with FIT in average-risk screening. Stool DNA had higher sensitivity for colorectal cancer and advanced precancerous lesions but lower specificity, increasing follow-up colonoscopy (Imperiale 2014, PMID 24645800).

A next-generation assay reported 93.9% sensitivity for colorectal cancer, 43.4% for advanced precancerous lesions and 90.6% specificity among participants without advanced neoplasia; cross-sectional performance does not prove mortality benefit or longitudinal adherence (Imperiale 2024, PMID 38477986).

Key unresolved comparisons are not only sensitivity and specificity but interval, cumulative false positives, colonoscopy demand, cost and equitable access.

Blood-based screening

The ECLIPSE validation study of a cfDNA blood test reported 83.1% sensitivity for colorectal cancer and 89.6% specificity for advanced neoplasia, but sensitivity for advanced precancerous lesions was 13.2% (Chung 2024, PMID 38477985). The low precursor sensitivity means a blood-first program may detect cancer while preventing fewer cancers than stool/endoscopic strategies.

Later blood-test validations report performance under different algorithms and populations, making head-to-head comparisons difficult (Shaukat 2025, PMID 40455622). Mortality, interval-cancer and repeated-adherence outcomes remain immature.

Polypectomy as prevention

The National Polyp Study observed a 53% lower colorectal-cancer mortality after adenoma removal than expected from population comparators over median 15.8 years (Zauber 2012, PMID 22356322). This supports prevention but is not a randomized no-polypectomy comparison.

Risk after removal remains stratified by baseline lesion. Advanced adenomas and large/dysplastic serrated lesions warrant surveillance; small low-risk lesions may return toward population risk (He 2020, PMID 31302144).

Harms

Harm Test most implicated Risk modifier
Perforation Colonoscopy/polypectomy Age, comorbidity, therapeutic complexity
Post-polypectomy bleeding Colonoscopy Lesion size/location, antithrombotics, technique
Cardiopulmonary/sedation event Sedated colonoscopy Frailty and cardiopulmonary disease
False positive Any noninvasive test Specificity, repeated rounds
False negative Any test Stage, lesion biology, sampling and interval
Overdiagnosis Cancer-detection strategies Competing mortality and indolent lesions
Incidental extracolonic finding CT colonography Downstream imaging/procedure cascade
Anxiety and financial burden All strategies Coverage and result-navigation system

Screening benefit is delayed. Harms are immediate; older-adult decisions must incorporate prior screening and competing mortality, not age alone.

Participation and inequity

Qualitative synthesis identifies practical barriers, fear, disgust, low perceived risk, distrust, clinician recommendation and test preference as interacting determinants (Honein-AbouHaidar 2016, PMID 27197277). Colonoscopy-specific synthesis adds preparation burden, embarrassment, pain/sedation and transport (Lim 2021, PMID 32694277). Stool-test perspectives include convenience alongside handling concerns and uncertainty about a positive result (Chin 2020, PMID 32740167).

Intervention Pathway target Failure if used alone
Mailed FIT Initial access/completion Positive tests may not reach colonoscopy
Patient navigation Multiple transitions Capacity constraints remain
Clinician reminder Recommendation Misses people without visits
Choice architecture Preference matching Choices without access are nominal
Weekend/local colonoscopy Procedure access Workforce and quality must be maintained
No-cost coverage Financial access Time, transport and trust remain

Hard-to-reach screening strategies work best at individual, provider and system levels simultaneously (Huang 2017, PMID 29546218). Post-positive-test adherence itself shows racial/ethnic and system disparities and should be a reported quality endpoint (Chaparro 2026, PMID 42517977).

Symptomatic early detection is not screening

Rectal bleeding, iron-deficiency anemia, persistent bowel-habit change, weight loss or obstruction require diagnostic evaluation regardless of screening age or prior negative test. Calling that evaluation “screening” can create inappropriate intervals and false reassurance.

A negative FIT lowers but does not eliminate cancer probability in symptomatic people; threshold-based symptomatic FIT evidence must be used within a safety-netted diagnostic pathway (Harnan 2024, PMID 39690130).

Program scoreboard

Outcome Best denominator
Invitation coverage All eligible residents
Test completion Invited residents
Positivity Completed tests
Colonoscopy completion Positive noninvasive tests
Time to colonoscopy Positive-test date
Adenoma/cancer detection Completed diagnostic colonoscopies
Stage distribution Screen-detected cancers
Interval cancer Person-time after negative screen
Major adverse event Completed procedures
Mortality Intention-to-screen population

Open questions

  • Will blood screening improve longitudinal participation enough to offset low advanced-precursor sensitivity? (Chung 2024, PMID 38477985)
  • Which FIT threshold maximizes mortality benefit within a fixed colonoscopy capacity? (Lee 2014, PMID 24658694)
  • How should colonoscopy invitation effects evolve at 15–20 years as participation and contamination accumulate? (Kaminski 2026, PMID 42102826)
  • Which interventions shorten positive-test-to-colonoscopy time across underserved groups? (Chaparro 2026, PMID 42517977)
  • Can serrated-detection quality measures reduce proximal interval cancer without excessive removal? (Corley 2014, PMID 24693890)

References

  1. US Preventive Services Task Force, et al. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977. PMID 34003218
  2. Bretthauer M, et al. Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death. N Engl J Med. 2022;387(17):1547-1556. PMID 36214590
  3. Wooldrage K, et al. Long-term effects of once-only flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: 21-year follow-up of the UK Flexible Sigmoidoscopy Screening randomised controlled trial. Lancet Gastroenterol Hepatol. 2024;9(9):811-824. PMID 39038482
  4. Doubeni CA, et al. Fecal Immunochemical Test Screening and Risk of Colorectal Cancer Death. JAMA Netw Open. 2024;7(7):e2423671. PMID 39028667
  5. Imperiale TF, et al. Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening. N Engl J Med. 2024;390(11):984-993. PMID 38477986
  6. Chung DC, et al. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. N Engl J Med. 2024;390(11):973-983. PMID 38477985
  7. Wolf AMD, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250-281. PMID 29846947
  8. Lee JK, et al. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160(3):171. PMID 24658694
  9. Castells A, et al. Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial. Lancet. 2025;405(10486):1231-1239. PMID 40158525
  10. Kaminski MF, et al. Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial. Lancet. 2026;407(10541):1787-1795. PMID 42102826
  11. Corley DA, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med. 2014;370(14):1298-306. PMID 24693890
  12. Wieszczy P, Regula J, Kaminski MF. Adenoma detection rate and risk of colorectal cancer. Best Pract Res Clin Gastroenterol. 2017;31(4):441-446. PMID 28842054
  13. Waldmann E, et al. Association of Adenoma Detection Rate and Adenoma Characteristics With Colorectal Cancer Mortality After Screening Colonoscopy. Clin Gastroenterol Hepatol. 2021;19(9):1890-1898. PMID 33878471
  14. Senore C, et al. Long-Term Follow-up of the Italian Flexible Sigmoidoscopy Screening Trial. Ann Intern Med. 2022;175(1):36-45. PMID 34748376
  15. Miller EA, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: long-term follow-up of the randomised US PLCO cancer screening trial. Lancet Gastroenterol Hepatol. 2019;4(2):101-110. PMID 30502933
  16. Holme Ø, et al. Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence and Mortality in Women and Men: A Randomized Trial. Ann Intern Med. 2018;168(11):775-782. PMID 29710125
  17. Imperiale TF, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370(14):1287-97. PMID 24645800
  18. Shaukat A, et al. Clinical Validation of a Circulating Tumor DNA-Based Blood Test to Screen for Colorectal Cancer. JAMA. 2025;334(1):56-63. PMID 40455622
  19. Zauber AG, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012;366(8):687-96. PMID 22356322
  20. He X, et al. Long-term Risk of Colorectal Cancer After Removal of Conventional Adenomas and Serrated Polyps. Gastroenterology. 2020;158(4):852-861.e4. PMID 31302144
  21. Honein-AbouHaidar GN, et al. Systematic Review and Meta-study Synthesis of Qualitative Studies Evaluating Facilitators and Barriers to Participation in Colorectal Cancer Screening. Cancer Epidemiol Biomarkers Prev. 2016;25(6):907-17. PMID 27197277
  22. Lim KT, et al. Barriers and facilitators towards colonoscopy: a qualitative systematic review. Eur J Cancer Prev. 2021;30(3):232-238. PMID 32694277
  23. Chin YH, et al. Evolving perspectives on stool testing for colorectal cancer: a qualitative systematic review. Eur J Cancer Prev. 2020;29(5):416-423. PMID 32740167
  24. Huang JL, et al. Approaching the Hard-to-Reach in Organized Colorectal Cancer Screening: an Overview of Individual, Provider and System Level Coping Strategies. AIMS Public Health. 2017;4(3):289-300. PMID 29546218
  25. Chaparro S, et al. Disparities in colonoscopy adherence and neoplasia detection after positive fecal immunochemical test: a retrospective matched cohort study. Cancer Causes Control. 2026;37(9). PMID 42517977
  26. Harnan S, et al. Faecal immunochemical tests for patients with symptoms suggestive of colorectal cancer: An updated systematic review and multiple-threshold meta-analysis of diagnostic test accuracy studies. Colorectal Dis. 2024;27(1). PMID 39690130